What eGFR decline rate is abnormal?

Annual eGFR loss >3 mL/min/1.73m2/year (or >5 mL/min/1.73m2/year in patients eGFR >45) is clinically significant. Compare to normal aging loss of ~0.5-1 mL/min/year. Requires >=3 measurements over >=3 months.

Is 40% eGFR decline a validated surrogate?

Yes. 40% eGFR decline over 2 years is FDA-accepted as a surrogate endpoint for ESRD in CKD clinical trials. These endpoints predict eventual ESRD with high fidelity.

How does eGFR slope monitoring change management?

Rapid eGFR decline (>3 mL/min/year) should trigger: medication review (nephrotoxins), blood pressure optimization (target <130/80), proteinuria reduction (RAAS blockade + SGLT2i), and nephrology referral.

eGFR Slope Decline Clinically Significant

Determine clinically significant eGFR decline rate. Loss >3 mL/min/1.73m2/year or 40% eGFR decline over 2 years is a validated surrogate endpoint predicting ESRD risk.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.

How to Use

Enter the values for the scenario you are assessing. Determine clinically significant eGFR decline rate. Loss >3 mL/min/1.73m2/year or 40% eGFR decline over 2 years is a validated surrogate endpoint predicting ESRD risk. Use the egfr slope significance result to inform your calculation.

Related Calculators

UACR Risk Stratification

Hyper-niche Medical

AKI to CKD Transition Risk